Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced its preliminary sales results for Q4 2022, reporting GAAP sales of $221 million, up from $210 million in Q4 2021. For the full year, GAAP sales reached $802 million, increasing from $703 million in 2021. The company expects a worldwide sales growth of 11-12% in 2023, not including new product launches like the Mobi Insulin Pump, under FDA review. The CEO highlighted strong customer retention and satisfaction for their t:slim X2 Insulin Pump.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will present an update on Wednesday, January 11, 2023, at 8:15 PM Eastern Time. The presentation will be available via a live webcast, with an archived recording accessible for 30 days on the company’s Investor Center website. Tandem Diabetes Care focuses on innovative insulin delivery solutions and is known for its t:slim X2 insulin pump featuring Control-IQ technology.

Tandem Diabetes Care (TNDM) has announced its definitive agreement to acquire AMF Medical, the Swiss developer of the Sigi™ Patch Pump. This acquisition is expected to expand Tandem's addressable market for insulin delivery solutions and enhance its product portfolio. The deal includes an initial payment of CHF 62.4 million, in addition to contingent earnout payments totaling up to CHF 129.6 million based on milestone achievements. The acquisition aims to accelerate product development, reduce waste, and offer additional customer access, with the transaction expected to close in January 2023.

Tandem Diabetes Care (NASDAQ: TNDM) has achieved the Great Place to Work Certification, with 84% of employees affirming it’s a great workplace, significantly higher than the national average. This recognition, based on employee feedback, highlights Tandem's commitment to a positive workplace culture, aligning with its core value of People First. The company has gained local accolades in San Diego and Boise for its work environment, emphasizing its focus on employee satisfaction.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced positive results from a multicenter study on the t:slim X2 insulin pump featuring Control-IQ technology for type 2 diabetes management. The study found significant improvements in glycemic control, with a 15% increase in time in range (3.6 hours/day). No hypoglycemia was reported. High satisfaction levels were observed among participants. The trial involved 30 adults across three centers. Notably, Control-IQ technology is not yet FDA-approved for type 2 diabetes use and was employed under an investigational device exemption.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leader in diabetes technology, will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022, at 9:00 AM Eastern Time. The presentation will be available via live webcast, and an archive will be accessible for 30 days. More details can be found on Tandem's Investor Center under the “Events & Presentations” section. Tandem is known for its innovative insulin delivery solutions, including the t:slim X2 insulin pump.

Tandem Diabetes Care reported its Q3 2022 results, highlighting a 35% increase in its worldwide installed customer base, surpassing 400,000. Total sales rose 14% to $204.5 million, driven by a nearly 70% surge in U.S. renewal pump shipments. Despite a gross profit increase of 8% to $104.4 million, the company faced a GAAP net loss of $49 million, compared to a profit in the prior year. The updated 2022 guidance estimates non-GAAP sales between $800 million and $805 million, down from previous expectations, amid cautious market conditions.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present updates at several investor conferences in November 2022. The presentations will take place at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 4:25 PM ET, the Jefferies London Healthcare Conference on November 15 at 12:20 PM GMT, and the Stifel 2022 Healthcare Conference on November 16 at 4:45 PM ET. All presentations will be webcast live with an archive available for 30 days on their Investor Center website.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to announce its third quarter 2022 results post-market close on November 2, 2022. A conference call and webcast, scheduled for 4:30 PM ET, will discuss the financial and operational results. Investors can access the live webcast via the Investor Center on their website. An archived version will be available for 30 days following the event.

As a prominent insulin delivery and diabetes technology firm, Tandem continues to innovate with products like the t:slim X2 insulin pump featuring Control-IQ technology.